Increased tissue factor pathway inhibitor in patients with acute myocardial infarction

No abstract is available for this paper.

• Publication year

  1997

• Venue

  American journal of hematology/oncology

• Publication date

  1997-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1096-8652(199707)55:4<183::AID-AJH3>3.0.CO;2-OPMID 9257877
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation

  1996cited by this paper
• Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.

  1996cited by this paper
• TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.

  1995cited by this paper
• An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.

  1995cited by this paper
• Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.

  1995cited by this paper
• Decreased Plasma Tissue Factor Pathway Inhibitor Levels in Patients with Thrombotic Thrombocytopenic Purpura

  1995cited by this paper
• Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI.

  1994cited by this paper
• Relationship of Tissue Factor Pathway Inhibitor Activity to Plasma Lipoproteins and Myocardial Infarction at a Young Age

  1994cited by this paper
• Atherosclerosis: what is it and why does it occur?

  1993cited by this paper
• Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation

  1993cited by this paper
• Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

  1993cited by this paper
• The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation

  1991cited by this paper
• Tissue factor pathway inhibitor with high anticoagulant activity is increased in post‐heparin plasma and in plasma from cancer patients

  1991cited by this paper
• Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.

  1991cited by this paper
• The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease.

  1989cited by this paper
• Factor VII and extrinsic pathway inhibitor in acute coronary disease

  1989cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper

• Tissue factor pathway inhibitor levels and atherothrombotic events in patients with chronic kidney disease or diabetes

  2025cites this paper
• Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?

  2023cites this paper
• Changes of fibrinolytic system in thrombolytic resuscitation of pulmonary thromboembolism‐induced cardiac arrest model

  2021cites this paper
• Heparanase as a potential player in SARS-CoV-2 infection and induced coagulopathy

  2021cites this paper
• Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation

  2021cites this paper
• Heparanase in the Coagulation System.

  2020cites this paper
• Detection of biomarkers using a novel proximity extension assay in patients with ST-elevation myocardial infarction.

  2018cites this paper
• Cancer-associated thrombosis.

  2016cites this paper
• Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.

  2014cites this paper
• Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor

  2014cites this paper
• Heparanase and Coagulation–New Insights

  2014cites this paper
• The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis.

  2013cites this paper
• In search for novel biomarkers of acute coronary syndrome.

  2012cites this paper
• Heparanase—A Link between Coagulation, Angiogenesis, and Cancer

  2012cites this paper
• Biomarkers of Atherosclerosis and Acute Coronary Syndromes - A Clinical Perspective

  2012cites this paper
• Traditional and Novel Risk Factors in Atherothrombosis

  2012cites this paper
• Cancer and Coagulation; Focusing on Tissue Factor and Heparanase

  2010cites this paper
• Circulating thrombotic and haemostatic components in patients with coronary artery disease

  2010cites this paper
• Heparanase procoagulant effects and inhibition by heparins.

  2010cites this paper
• Biomarkers in ischemic cardiac syndromes

  2010cites this paper
• Biochemical characterization of plasma‐derived tissue factor pathway inhibitor: post‐translational modification of free, full‐length form with particular reference to the sugar chain

  2009cites this paper
• THE ASSOCIATION OF CELECOXIB, ROFECOXIB, AND NON-SELECTIVE NONSTEROIDAL ANTI-INFLAMMATORY MEDICATIONS WITH INDICES OF THROMBOSIS AND ENDOTHELIAL FUNCTION IN THE MULTI-ETHNIC STUDY

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Clinical and experimental studies on treatment of acute mesenteric ischemia

  2009cites this paper
• Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis

  2009cites this paper
• Heparanase coagulation and cancer progression.

  2009cites this paper
• Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level

  2009cites this paper
• Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.

  2008cites this paper
• Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis

  2008cites this paper
• Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes.

  2006cites this paper
• TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications.

  2005cites this paper
• Diabetes mellitus tipo 2: papel de los depósitos de amiloide

  2005cites this paper
• Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries.

  2004cites this paper
• Blood Coagulation and Atherothrombosis Hiroshi Ashikaga

  2004cites this paper
• Tissue factor pathway inhibitor in thrombosis and beyond.

  2004cites this paper
• Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension.

  2003cites this paper
• Marcadores de lesión endotelial implicados en la trombosis y fibrinolisis en la diabetes mellitus

  2003cites this paper
• Tissue Factor in Acute Coronary Syndromes

  2003cites this paper
• Tissue factor pathway inhibitors as a novel approach to antithrombotic therapy.

  2003cites this paper
• Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma

  2003cites this paper
• Plasma plasmin–α2‐plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension

  2003cites this paper
• Observation on tissue factor pathway and some other coagulation parameters during the onset of acute cerebrocardiac thrombotic diseases.

  2002cites this paper
• Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short‐term low‐molecular‐weight heparin administration

  2002cites this paper
• Tissue factor and coronary artery disease.

  2002cites this paper
• Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects.

  2002cites this paper
• Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation.

  2001cites this paper
• Charakterisierung von Thrombozytenfunktion und Thrombozyten-Leukozyten Interaktionen im Rahmen von Koronarinterventionen unter einer Therapie mit Clopidogrel

  2001cites this paper
• Structure and Biology of Tissue Factor Pathway Inhibitor

  2001influential citation
• Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders

  2001cites this paper
• Combination of a Brief Irrigation With Tissue Factor Pathway Inhibitor (TFPI) and Adenovirus-Mediated Local TFPI Gene Transfer Additively Reduces Neointima Formation in Balloon-Injured Rabbit Carotid Arteries

  2001cites this paper
• Production of Tissue Factor Pathway Inhibitor in Cardiomyocytes and Its Upregulation by Interleukin-1

  2001cites this paper
• Disfunción endotelial, alteraciones de la coagulación e hiperhomocisteinemia en la diabetes mellitus

  2001cites this paper
• Anomalies de la voie du facteur tissulaire en pathologie thrombotique veineuse

  2000cites this paper
• Hemostatic Abnormalities in Patients With Thrombotic Complications on Maintenance Hemodialysis

  2000cites this paper
• Altered Plasma Antigen Levels of Tissue Factor Pathway Inhibitor During Open-Heart Surgery

  2000cites this paper
• The effect of heparin on tissue factor and tissue factor pathway inhibitor in patients with acute myocardial infarction.

  2000cites this paper
• A New T-287C Polymorphism in the 5’ Regulatory Region of the Tissue Factor Pathway Inhibitor Gene

  2000cites this paper
• Tissue factor pathway inhibitor for cardiovascular disorders

  2000cites this paper
• Changes of Hemostatic Molecular Markers After Gynecological Surgery

  2000cites this paper
• Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration

  1999cites this paper
• Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.

  1999cites this paper
• Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease

  1999cites this paper
• Adenovirus-mediated local expression of human tissue factor pathway inhibitor eliminates shear stress-induced recurrent thrombosis in the injured carotid artery of the rabbit.

  1999cites this paper
• Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation

  1998cites this paper
• Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.

  1998cites this paper
• Sodium Salicylate Enhances Expression of Tissue Factor (TF) in Human Adherent Monocytes and in Whole Blood

  1998cites this paper
• C-399T Polymorphism in the Promoter Region of Human Tissue Factor Pathway Inhibitor (TFPI) Gene Does not Change the Plasma TFPI Antigen Level and Does not Cause Venous Thrombosis

  1998cites this paper
• 内皮細胞結合型外因系凝固インヒビター(TFPI)と高脂血症

  1997cites this paper